Developments on the generic front

1. Teva and Medicis settled Solodyn case after Teva's at-risk launch. Teva ceased shipping, was relived by Medicis from any claim, but would launch again in 2011 or earlier, under certain circumstances.

2. Impax started co-promoting Pristiq as part of the Effexor XR settlement.

Biologics

Roche finally secured the Genentech deal.

In the mean time, generic biologic legislation has regained momentum.

Merck and Shering Plough Merge